Skip to main content

11-07-2024 | Multiple Sclerosis | News

EAN 2024

Frexalimab efficacy for MS sustained through 48 weeks

Author: Lucy Piper

medwireNews: The second-generation anti-CD40L monoclonal antibody frexalimab shows sustained benefit over 48 weeks in patients with relapsing multiple sclerosis (MS), show findings presented at the 10th Congress of the European Academy of Neurology.

Related topics